Mary DiBiase - 11 Mar 2024 Form 4 Insider Report for X4 Pharmaceuticals, Inc (XFOR)

Role
Chief Operating Officer
Signature
/s/ Adam S. Mostafa, attorney-in-fact
Issuer symbol
XFOR
Transactions as of
11 Mar 2024
Net transactions value
-$13,591
Form type
4
Filing time
11 Mar 2024, 17:19:38 UTC
Previous filing
16 Feb 2024
Next filing
11 Sep 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XFOR Common Stock Sale $13,591 -15,409 -5% $0.8820 291,752 11 Mar 2024 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.863 to $0.91, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 2, 2023.